Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 909 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT06547528RecruitingPhase 1
Testing ONO-4685 for T cell lymphoma and CLL/SLL
This trial tests a new drug, ONO-4685, for people with certain types of T cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has not responded to standard treatments or cannot tolerate them. The goal is to see if the drug is safe and tolerable.
Nagoya, Aichi-kenAges 18 years+ - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
Boston, MassachusettsAges 18 years+ - NCT06554600RecruitingPhase 2
Study of zanubrutinib plus polatuzumab, bendamustine, and rituximab for relapsed DLBCL
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hanzhou, ZhejiangAges 18–75 - NCT06561854RecruitingPhase 3
Comparing multiple myeloma treatment with and without dexamethasone
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
ParisAges 18 years+ - NCT06563596RecruitingPhase 2
Study of epcoritamab, zanubrutinib, and rituximab for relapsed lymphoma
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06567197Recruiting
MS treatment with stem cell transplant in the Netherlands
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
AmsterdamAges 18–65 - NCT06569550Recruiting
Fatigue treatment study for multiple sclerosis
This trial tests a brain stimulation therapy designed to reduce fatigue in people with multiple sclerosis. If you experience moderate to severe fatigue and have a stable medication routine, this study might help determine if a non-invasive treatment can improve your energy levels.
Hvidovre, Capital RegionAges 18–65 - NCT06586177Recruiting
Study on Long-Term Effects of B Cell Therapies for MS
This study looks at how B cell therapies (a type of medicine for MS) create a long-lasting effect in people with relapsing-remitting multiple sclerosis. It aims to understand how these treatments work over time so doctors can better predict benefits and risks.
DüsseldorfAges 18–60 - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Chandler, ArizonaAges 18 years+ - NCT06593145RecruitingPhase 1
CAR-T therapy for relapsed CD19+ B-cell cancers
This trial tests a new type of CAR-T cell therapy for people with certain B-cell cancers (leukemia or lymphoma) that have not responded to standard treatments. It aims to see if these specially engineered immune cells can attack and destroy the cancer.
Warsaw, Ul. Banacha 1aAges 18–65 - NCT07007195RecruitingEarly Phase 1
Smart smell app to help you quit smoking
This study tests a smartphone app that uses your sense of smell to help you quit smoking. You'll use nicotine replacement therapy (like patches or gum) and the app to avoid relapse.
Houston, TexasAges 18 years+ - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT06096038RecruitingPhase 1
CAR-T cell therapy for head and neck cancer
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06609369RecruitingPhase 2
Sleep and smoking relapse study
This study tests whether improving sleep can help people quit smoking and avoid relapse. It uses brain scans, a quitting medication, and counseling.
New Haven, ConnecticutAges 18–65 - NCT06611280Recruiting
Deuterium imaging study for people with multiple sclerosis
This study uses a special MRI technique to look at how brain cells use energy in people with relapsing-remitting MS. It may help doctors better understand MS and guide future treatments.
Aarhus CAges 18–60 - NCT06613217RecruitingPhase 1
Oral PCLX-001 for relapsed or refractory AML
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
Houston, TexasAges 18 years+ - NCT06613334Recruiting
Voice recordings to predict schizophrenia relapse
This study tests whether voice recordings can help predict when someone with schizophrenia might have a relapse. It is for people who are stable now and take certain medications.
Paris, ParisAges 18–60 - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT06618755Recruiting
Staying sober after detox: a coaching study
This study tests if motivational interviews after hospital detox help people with alcohol use disorder stay completely sober for one year. It might help you if you are committed to full abstinence and have a phone available.
MontpellierAges 18 years+ - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 909 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.